1. Show or hide comments about the document.

  2. Search over the document's text.

  3. Share the document through social networks or e-mail.

  4. After selecting an area on the page.

  5. ...you can:
    copy the text
    share the segment
    comment
    cite the document

Fall 2017
ISSN 0890-913X
Volume 32, Number 3

Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!

Raymond J. March, Texas Tech University
Download Share e-mail
  • << Back to editing
  • Previous version by
  • << Older
  • Newer >>
  • Revert to this one
  • Edit
  • Fullscreen
  • Show comments
  •  
  •  
  •  
  •  
  • Zoom:
     
     
  • Page:  / 19
  •  
  •  
  •  
  • Line spacing:
     
     
  • Word spacing:
     
     
  • Search:FindClose
 
search results
 
 
 
 
 
 
 
 
 
 
 
432
648
1
0
/index.php?action=ajax&rs=GDMgetPage&rsargs[]=2017 Journal of Private Enterprise vol 32 no 3 Fall parte6.pdf&rsargs[]=0
TheJournalofPrivateEnterprise32(3),2017,7592EntrepreneurshipinOff-LabelDrugPrescription:JustWhattheDoctorOrdered!RaymondJ.MarchTexasTechUniversity______________________________________________________AbstractThispaperfindsthatphysiciansandpharmaceuticalcompaniesworkingasentrepreneurialactorswereabletobetterservepatientsbyfindingeffectivealternativeusesofthreedrugs.Iexamineoff-labeldrugprescriptionwithinanentrepreneurialframeworkbyexaminingthedevelopmentprocessesofaspirin,Viagra,andminoxidil.Ineachcase,themedicalcommunityreachedresearchandtreatmentconclusionsquickerthantheFDAdid.Theseexamplesprovidecounterevidencetotheviewthatoff-labelprescriptionisrecklessandrequiresadditionalgovernmentaloversightduetoalackofsufficienttesting.______________________________________________________JELCodes:I18,I12,K23Keywords:healtheconomics,off-labeldrugprescription,entrepreneurship,FDAI.IntroductionAnylegallyprescribeddrugintheUnitedStatesmustundergoalengthy,costly,anduncertainprocessenforcedbytheFoodandDrugAdministration(FDA).Thetimebetweendrugdiscoveryandapprovalaveragessixteenyears,andtheprobabilityofapprovalforhumanuseisapproximately10percent(Stossel2015).Completingthisapprovalprocessrequiresanaverageinvestmentof$403million(Demasi,Hansen,andGrabowoski2003).1ThehighcostofFDAdrugapprovalcreatessignificantbarrierstoentryandreducesthenumberofpharmaceuticalsavailabletoconsumers(Tabarrok2000,2009).Physiciansareleftwithfewoptionstoservepatients(Benson2004).Despitethesehighbarrierstoentry,physicianscanexerciseanentrepreneurialroleintheirpracticesbyprescribingandrecommendingpharmaceuticalsoff-label.AsnotedbySalbu(1999),1Theauthorsprovidethisestimatein2000dollars.In2016dollars,$403millionisapproximately$560million.
GLIFOS-digital_archive